Research To Practice | Oncology Videos

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Renal Cell Carcinoma and Bladder Cancer — Faculty Presentation 1: Kidney Cancer — Prof Thomas Powles CME information and select publications

Featuring perspectives from Drs Mansoor Raza Mirza, Amit M Oza and Richard T Penson, moderated by Dr Joyce F Liu, including the following topics: • Optimal Genomic Evaluation of and Targeted Therapies for Newly Diagnosed Advanced Ovarian Cancer — Dr Mirza o Introduction (0:00) o Case: A morbidly obese woman in her mid 40s who is a Jehovah's Witness with ovarian cancer and a germline BRCA2 mutation — Lyndsay J Willmott, MD (1:10) o Case: A woman in her early 50s with BRCA wild-type, homologous recombination repair deficiency (HRD)-negative Stage IV ovarian cancer, a large pleural effusion and ascites — Kellie E Schneider, MD (7:16) o Faculty presentation: Dr Mirza (13:51) • PARP Inhibitors for Relapsed/Refractory Ovarian Cancer — Dr Oza o Case: A woman in her mid 60s with recurrent BRCA wild-type ovarian cancer in ongoing and durable remission with paclitaxel/carboplatin followed by maintenance niraparib — John K Chan, MD (26:13) o Case: A woman in her early 50s with a germline BRCA2 mutation and recurrent platinum-sensitive ovarian cancer who received paclitaxel/carboplatin/bevacizumab and maintenance olaparib/bevacizumab — Thomas P Morrissey, MD (32:09) o Faculty presentation: Dr Oza (36:55) • Rationale for and Available Data with PARP Inhibitors in Combination with Other Anticancer Therapies for Advanced Ovarian Cancer — Dr Liu o Case: A woman in her early 20s with newly diagnosed Stage IV, low-grade serous carcinoma of the ovary with pleural effusions — Dana M Chase, MD (48:55) o Case: A woman in her late 40s with high-grade serous ovarian cancer who received neoadjuvant chemotherapy on the Phase III FIRST trial and undergoes R0 debulking surgery — Dr Schneider (52:51) o Faculty presentation: Dr Liu (57:39) • Novel Agents for the Treatment of Ovarian Cancer — Dr Penson o Case: A woman in her mid 60s with multiregimen-refractory metastatic ovarian cancer who receives paclitaxel/tumor treating fields on the INNOVATE-3 trial and develops dermatologic toxicity — Dr Chan (1:07:19) o Cases: A woman in her early 70s with multiple comorbidities and extensively treated recurrent, platinum-resistant BRCA wild-type, HRD-negative, PD-L1-positive, FR-alpha-mutant ovarian cancer and a woman in her mid 40s with a germline BRCA1 mutation and multiregimen-recurrent FR-alpha-mutant carcinomatosis — Dr Chase and Dr Willmott (1:11:00) o Faculty presentation: Dr Penson (1:18:20) CME information and select publications

Featuring an interview with Dr John Allan, including the following topics: • Update on key studies of acalabrutinib in the front-line setting (0:00) • Updated data from the GLOW study: First-line fixed-duration ibrutinib and venetoclax compared to chlorambucil and Obinutuzumab (21:11) • Treatment outcomes after achieving undetectable minimal residual disease (MRD) with first-line ibrutinib and venetoclax: Updated analysis of the CAPTIVATE trial (35:06) • Ibrutinib/venetoclax with MRD-driven duration of treatment: Updated analysis of the FLAIR trial (48:08) • Acalabrutinib with venetoclax and obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) in a population enriched for high-risk disease (50:49) • Risk factors to predict failure of therapy using fixed-duration venetoclax/obinutuzumab (53:22) • Updates on the ALPINE and BRUIN studies of zanubrutinib and pirtobrutinib, respectively, for relapsed/refractory CLL (56:15) • Emerging data with novel Bcl-2 inhibitors (1:11:26) • Evolving data with subcutaneous epcoritamab for patients with Richter's transformation and CLL (1:14:37) CME information and select publications

Featuring perspectives from Dr John Strickler, including the following topics: • Introduction: ASCO Guidelines for the Treatment of Metastatic Colorectal Cancer (0:00) • Case: A woman in her mid 70s with metastatic colon cancer — Sunil Gandhi, MD (11:14) • Case: A man in his late 70s with T3N0 MSS adenocarcinoma of the colon who is ctDNA-negative after colectomy and would like to avoid chemotherapy — Georges Azzi, MD (22:01) • Case: A woman in her early 80s with mismatch repair-proficient Stage IIIC high-risk adenocarcinoma of the colon with neuroendocrine features after adjuvant FOLFOX — Gigi Chen, MD (25:39) • Case: A man in his late 40s with a HER2-amplified ascending colon adenocarcinoma and liver metastases who undergoes perioperative FOLFOXIRI and liver resection — Swati Vishwanathan, MD (32:54) • Case: A man in his late 50s with metastatic adenocarcinoma of the colon and disease progression after multiple lines of chemotherapy — Priya Rudolph, MD, PhD (44:31) • Case: A man in his late 70s with metastatic rectal adenocarcinoma, high tumor mutational burden and multiple genetic alterations by liquid biopsy, including KRAS G12C — Shaachi Gupta, MD, MPH (48:31) • Case: A man in his early 60s with rectal cancer, synchronous liver metastases and lung oligometastases after perioperative FOLFOX and resection of the primary and liver metastases — Dr Gupta (55:36) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer — Faculty Presentation 2: Evidence-Based Utilization of Other Therapeutic Approaches — A Oliver Sartor, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer — Faculty Presentation 1: Optimizing the Use of Hormonal Therapy in Prostate Cancer Management — Tanya B Dorff, MD CME information and select publications

Featuring perspectives from Drs Tanya Dorff and A Oliver Sartor, including the following topics: • Introduction (0:00) • Castration-Sensitive Prostate Cancer (5:26) • PARP Inhibitors in Castration-Resistant Disease (23:00) • Radiopharmaceuticals (39:46) CME information and select publications

Featuring perspectives from Drs Eric Lee, Neil Morganstein and Swati Vishwanathan, including the following topics: • Gastroesophageal Cancers — Zev Wainberg, MD, MSc o Introduction (0:00) o Systemic therapy considerations for HER2-negative localized gastroesophageal cancers (4:33) o First-line systemic therapy for metastatic esophageal or gastric cancer (10:05) o Zolbetuximab/chemotherapy as first-line treatment for HER2-negative, locally advanced unresectable or metastatic gastric and gastroesophageal junction cancers (16:19) o Repeat tissue biopsy versus circulating tumor DNA testing for HER2-positive GI cancers after disease progression on first-line therapy (20:59) o Trastuzumab deruxtecan as second-line therapy for HER2-positive gastric cancer; management of CNS disease (25:05) • Hepatobiliary Cancers — Lipika Goyal, MD, MPhil o Tissue biopsy for suspected hepatocellular carcinoma (HCC) (29:59) o Atezolizumab/bevacizumab versus durvalumab/tremelimumab as first-line therapy for HCC; disease etiology and response to treatment (33:34) o Liver-directed therapy in the era of effective novel systemic regimens (40:50) o First-line, single-agent immunotherapy for HCC (44:33) o Sequencing tyrosine kinase inhibitors for patients with HCC with and without contraindications to immunotherapy (47:46) o Survival benefit with durvalumab/gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) in the TOPAZ-1 trial — A new standard? (51:25) o Spectrum of targetable genetic alterations in BTCs; novel FGFR2 inhibitors for cholangiocarcinoma (54:28) CME information and select publications

Oncology Today with Dr Neil Love: Special Edition — Current Management of Hepatobiliary Cancers — Dr Lipika Goyal Visit our website for more publications

Oncology Today with Dr Neil Love: Special Edition — Current Management of Hepatobiliary Cancers — Dr Zev Wainberg Visit our website for more publications